The Food and Drug Administration awarded a $760,505 definitive contract to University of Strathclyde on November 2, 2026, for a four-year effort titled "Enhancing Regulatory Confidence in Pediatric Bioequivalence Through Validated TIM Based Mechanistic Platforms and Model Integrated Evidence," with performance completion targeted for November 1, 2030.
The originating solicitation is the FY26 FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science, a Special Notice issued under FAR 6.102(d)(2) and 35.016 seeking extramural research proposals to advance regulatory science across FDA-regulated domains. The announcement prioritizes modernizing development and evaluation of FDA-regulated products, strengthening post-market surveillance and labeling, and invigorating public health preparedness. The contract is firm fixed price with no set-aside applied. Place of performance is Great Britain, United Kingdom. The research area aligns with NAICS 541714 (Research and Development in Biotechnology) and PSC code AJ11 (General Science and Technology R&D Services).